Mexico Whenever the international investor community contemplates doing business in Mexico’s life science sector, the primary appeal usually derives from the sheer size of the marketplace and its underlying growth potential associated with trends in the country’s population demographics. Much attention is thus given over to devising strategies to win public…
Mexico Valued at USD 7.28 billion, the Mexican pharma market stands out within Latin America, ranking second only to Brazil, and registering a solid compound annual growth rate of six percent according to a 2023 CANIFARMA and INEGI study. That makes it, on paper, appear a highly attractive sector for investment,…
Italy The top 10 pharma manufacturing companies in Italy, as collated by MonitorItalia and ranked by production value in 2022. Pfizer tops the list, followed by Novartis, and local player Chiesi. The remainder of the list is populated by familiar names from multinational pharma, although another Italian firm – Alfasigma –…
Mexico Vincenzo D’Elia discusses the creation of Alfasigma’s Mexican affiliate – now solidly established after 14 years – and the company’s local strategy and market approach. He emphasizes the importance of understanding market dynamics for localized portfolio selection, highlights the company’s decision not to engage in government contracts, and comments on…
Italy Some of the biggest pharma and healthcare stories coming out of Italy, including Italy’s antitrust investigation of Novartis and Genentech; Johnson & Johnson’s EUR 125 million investment in its Italian manufacturing site; Chiesi Farmaceutici’s licensing agreement with Gossamer Bio for a pulmonary hypertension drug, and Menarini and Insilico’s oncology partnership.…
Italy A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between Venatorx Pharmaceuticals and Menarini, and the country’s drop in healthcare spending. Stevanato Group Announces Public Offering of Ordinary Shares…
Italy The latest news from the Italian healthcare and life sciences industries, including the final piece in Angelini’s updated leadership team; the country’s digital health investment timetable; and the details of Menarini’s Europe commercialisation deal for Karyopharm’s NEXPOVIO in Europe. Angelini Pharma Appoints Rafal Kaminski as New Chief Scientific Officer…
Italy A roundup of some of the most important recent stories from Italian pharma, including an in-depth interview with Menarini CEO Elcin Barker Ergun, a public health management crisis in the south of the country, Chiesi’s latest mobile health partnership, and the potential rollout of COVID-19 vaccines in January 2021. …
Switzerland Alfasigma Switzerland’s Dr Tytus Litynski introduces the Italian firm’s diversified portfolio of both Rx drugs and food supplements in Switzerland, why internal innovation remains the company’s core focus, and how stakeholder relations have had to evolve in the COVID-19 era. One advantage of being a family-owned rather than a…
Tunisia Slim Chouchane, general director of Alfasigma in Tunisia, discusses the integration with Sigma Tau, the Italian company acquired by Alfa Wassermann in 2016, Chouchane retraces the incredible success of Alfa Wassermann’s products over his 17 years with the company and his responsibility for the company’s sound growth in the region.…
See our Cookie Privacy Policy Here
